Cargando…

Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19

In 2021, data from global disease monitoring and infection surveillance programs have shown that vaccination programs have reduced the incidence of SARS-CoV-2 infection and hospitalization and mortality rates. Currently, the US Centers for Disease Control and Prevention (CDC) identifies a fully vacc...

Descripción completa

Detalles Bibliográficos
Autor principal: Parums, Dinah V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647456/
https://www.ncbi.nlm.nih.gov/pubmed/34848673
http://dx.doi.org/10.12659/MSM.935624
_version_ 1784610608255074304
author Parums, Dinah V.
author_facet Parums, Dinah V.
author_sort Parums, Dinah V.
collection PubMed
description In 2021, data from global disease monitoring and infection surveillance programs have shown that vaccination programs have reduced the incidence of SARS-CoV-2 infection and hospitalization and mortality rates. Currently, the US Centers for Disease Control and Prevention (CDC) identifies a fully vaccinated individual as being ≥14 days after the completion of all the recommended doses of a COVID-19 vaccine that has been authorized by the US Food and Drug Administration (FDA). A partially vaccinated individual is <14 days following primary vaccination or has not completed the vaccination program. Clinical studies and data on the vaccine status of populations have identified breakthrough COVID-19 cases in fully vaccinated individuals at 14 or more days after completing the recommended dose of an authorized SARS-CoV-2 vaccine. This Editorial presents an update on what has been learned in the past year on SARS-CoV-2 vaccine responses and breakthrough COVID-19.
format Online
Article
Text
id pubmed-8647456
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-86474562021-12-30 Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19 Parums, Dinah V. Med Sci Monit Editorial In 2021, data from global disease monitoring and infection surveillance programs have shown that vaccination programs have reduced the incidence of SARS-CoV-2 infection and hospitalization and mortality rates. Currently, the US Centers for Disease Control and Prevention (CDC) identifies a fully vaccinated individual as being ≥14 days after the completion of all the recommended doses of a COVID-19 vaccine that has been authorized by the US Food and Drug Administration (FDA). A partially vaccinated individual is <14 days following primary vaccination or has not completed the vaccination program. Clinical studies and data on the vaccine status of populations have identified breakthrough COVID-19 cases in fully vaccinated individuals at 14 or more days after completing the recommended dose of an authorized SARS-CoV-2 vaccine. This Editorial presents an update on what has been learned in the past year on SARS-CoV-2 vaccine responses and breakthrough COVID-19. International Scientific Literature, Inc. 2021-12-01 /pmc/articles/PMC8647456/ /pubmed/34848673 http://dx.doi.org/10.12659/MSM.935624 Text en © Med Sci Monit, 2021 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Editorial
Parums, Dinah V.
Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
title Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
title_full Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
title_fullStr Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
title_full_unstemmed Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
title_short Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
title_sort editorial: sars-cov-2 vaccine responses and breakthrough covid-19
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647456/
https://www.ncbi.nlm.nih.gov/pubmed/34848673
http://dx.doi.org/10.12659/MSM.935624
work_keys_str_mv AT parumsdinahv editorialsarscov2vaccineresponsesandbreakthroughcovid19